JPMorgan investor day: What to expect from the bank's forecasts
To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.
JP Morgan Chase's 2025 Investor Day is underway. Some of the things we are watching, commentary on tariffs, the company's financial outlook, tech spending and succession planning. First up, how the bank is assessing the early impact of tariffs. JP Morgan saying tariffs could hurt some parts of the business, like wholesale commercial and industrial loans, depending on which industries are hit and how much of the costs could be passed on to the consumer. The firm's consumer and community banking head said consumer sentiment is worsen worsening, but it's not yet translating into changes in spending. Very interesting economic outlook there. We're also watching the firm's outlook for 2025, the bank saying no big changes, maintaining its full year net interest income forecast of $94.5 billion, essentially in line with estimates. The bank will revisit its guidance in its second quarter earnings report that comes a couple months from now. JPM says it's positioned to deliver strong returns across a range of macroeconomic conditions and the reserves reflect the current level of uncertainty. Excess capital hitting around $57 billion in the first quarter, making the firm quote positioned to protect and grow the franchise under a range of circumstances. Another thing to watch, tech spend for the year will be about 18 billion. The firm says it's helping increase efficient efficiencies, particularly from none other than AI. The firm will also revisit resist headcount growth and leverage efficiency of its current staff as well. We're also of course watching for an update on Jamie Diamond's potential retirement. Last year, Diamond said he had less than five years left and investors are eager to learn more about his succession planning. Of course, we will bring you any of those headlines as we get them.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why Domo (DOMO) Shares Are Sliding Today
What Happened? Shares of data visualization and business intelligence company Domo (NASDAQ:DOMO) fell 4.1% in the pre-market session after investors appeared to take profits following a recent surge in the stock's price. The decline followed a period of strong performance, with the stock recently touching a new 52-week high. This upward momentum was fueled by positive news, including a first-quarter earnings report where revenue beat analyst expectations and the company issued strong guidance for the upcoming quarter. Analyst sentiment had also been positive, with Stephens & Co. initiating coverage with an "Overweight" rating and other firms reiterating bullish views. Given the absence of any specific negative news, the pre-market drop appeared to be driven by investors cashing in on the recent gains. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Domo? Access our full analysis report here, it's free. What Is The Market Telling Us Domo's shares are very volatile and have had 28 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 10 days ago when the stock gained 5.8% on the news that investment firm Stephens & Co. initiated coverage on the stock with an "Overweight" rating and a $19 price target. An "Overweight" rating suggested that the analyst, Brett Huff, believed Domo's stock had the potential to perform better than other stocks in the market. This positive outlook from a Wall Street firm often attracted investor attention. The initiation of coverage by a new analyst can increase visibility for a company among institutional and retail investors. The $19 price target represented a significant premium to the stock's recent trading levels, signaling the firm's confidence in the company's future performance. Domo is up 125% since the beginning of the year, and at $15.95 per share, it is trading close to its 52-week high of $16.29 from July 2025. Investors who bought $1,000 worth of Domo's shares 5 years ago would now be looking at an investment worth $507.00. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Crude Oil Rallies as President Trump Imposes a New Deadline on Russia
September WTI crude oil (CLU25) today is up +1.34 (+2.06%), and September RBOB gasoline (RBU25) is up +0.0328 (+1.59%). Crude oil and gasoline prices today are up sharply at 1-week highs. Concerns about the possibility of tighter global oil supplies are lifting crude prices today after President Trump said he would move up the deadline for Russia to agree to a truce with Ukraine. Crude prices also rose today after the S&P 500 rallied to a new record high, indicating confidence in the economic outlook that supports energy demand. In addition, positive trade news supports energy demand and crude prices after the EU and the US agreed to a trade deal and after the South China Post reported that the US and China will extend their trade truce for another three months. Today's stronger dollar is limiting gains in crude. More News from Barchart Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Crude prices jumped today after President Trump said he would impose a new deadline of 10-12 days for Russia to reach a truce with Ukraine before he increases sanctions on Russian energy exports, up from a previous deadline of 50 days. JPMorgan Chase warned that if enforced, oil markets would be unable to ignore the impact of triple-digit tariffs on Russian oil, given the significant scale of Russian exports and limited OPEC spare capacity, which could potentially lead to a supply shock. The European Union recently approved fresh sanctions on Russian oil due to its aggression against Ukraine. The sanctions package includes cutting off 20 more Russian banks from the international payments system SWIFT, as well as restrictions imposed on Russian petroleum refined in other countries. A large oil refinery in India, part-owned by Russia's Rosneft PJSC, was also blacklisted. Additionally, 105 more ships in Russia's shadow fleet were sanctioned, pushing the number of sanctioned ships above 400. In a supportive factor for oil prices, Bloomberg reported on July 10 that OPEC+ is discussing a pause in further production increases from October, following its next monthly hike in September of 548,000 barrels. OPEC+ may be concerned about a slowdown in global oil demand in the second half of this year that could lead to a supply glut if the group keeps boosting production. The International Energy Agency said inventories have been accumulating at a rate of 1 million bpd and that the global crude oil market faces a surplus by Q4-2025 equivalent to 1.5% of global crude consumption. Concern about a global oil glut is negative for crude prices. On July 5, OPEC+ agreed to raise its crude production by 548,000 barrels per day (bpd) beginning August 1, exceeding expectations of a 411,000 bpd increase. Saudi Arabia also stated that additional similar-sized increases in crude output could follow, which is viewed as a strategy to reduce oil prices and penalize overproducing OPEC+ members, such as Kazakhstan and Iraq. OPEC+ is boosting output to reverse the 2-year-long production cut, gradually restoring a total of 2.2 million bpd of production by September 2026. On May 31, OPEC+ agreed to a 411,000 bpd increase in crude production for July, following the same 411,000 bpd hike for June. June crude production rose +360,000 bpd to a 1.5-year high of 28.10 million bpd. Oil prices have been undercut by expectations for Iraq to boost crude exports from its northern Kurdish region through the Iraq-Turkey pipeline, where oil exports have been halted since March 2023. The Iraqi government approved a plan for the semi-autonomous Kurdish region to resume oil exports. Kurdistan expects to supply Iraq's crude market with 230,000 bpd of crude once exports resume. Iraq is the second-largest oil producer in OPEC. An increase in crude oil held worldwide on tankers is bearish for oil prices. Vortexa reported today that crude oil stored on tankers that have been stationary for at least seven days rose by +23% w/w to 84.99 million bbl in the week ended July 25. Last Wednesday's weekly EIA report showed that (1) US crude oil inventories as of July 18 were -8.6% below the seasonal 5-year average, (2) gasoline inventories were +0.2% above the seasonal 5-year average, and (3) distillate inventories were -18.5% below the 5-year seasonal average. US crude oil production in the week ending July 18 fell -0.8% w/w to 13.273 million bpd, modestly below the record high of 13.631 million bpd posted in the week of 12/6/2024. Baker Hughes reported Flast riday that the number of active US oil rigs in the week ending July 22 decreased by -7 rigs to a new 3.75-year low of 415 rigs. Over the past 2.5 years, the number of US oil rigs has fallen sharply from the 5.25-year high of 627 rigs reported in December 2022. On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
an hour ago
- Yahoo
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
The second-quarter 2025 reporting cycle for the Medical sector is about to pick up pace this week, as most firms are slated to share their earnings results over the next two weeks. The sector mainly comprises pharma/biotech and medical device companies. The earnings season for the drug and biotech sector kicked off around mid-July when bellwether Johnson & Johnson reported strong second-quarter results, beating estimates for earnings and sales. J&J consequently raised its total revenue expectation as well as its adjusted earnings expectation for the year. Among other pharma bigwigs, Novartis beat second-quarter earnings and revenue estimates, driven by a year-over-year increase in sales of key drugs. Based on strong momentum, Novartis raised its annual guidance for core operating income. Roche also posted solid growth in the first half of 2025 as high demand for key drugs like Phesgo (breast cancer), Xolair (food allergies), Hemlibra (hemophilia A), Vabysmo (severe eye diseases) and Ocrevus (multiple sclerosis) offset the decline in sales of legacy drugs. Per the Earnings Trends report, as of July 23, 15% of the companies in the Medical sector — representing 27.2% of the sector's market capitalization — reported quarterly earnings. Of these, 88.9% outperformed earnings estimates, while 100% beat the same for revenues. Earnings increased 0.4% year over year, while revenues increased 10.2%. Overall, second-quarter earnings of the Medical sector are expected to increase 0.9%, while sales are expected to rise 7.9% from the year-ago quarter. Merck MRK, AstraZeneca AZN, Bristol Myers BMY, AbbVie ABBV and Moderna MRNA are all slated to release theirquarterly results this week. Let us see how these biotech/pharma companies are likely to have performed in the soon-to-be-reported quarter. Merck Merck has an encouraging earnings track record. It beat earnings estimates in each of the last four quarters, delivering an average earnings surprise of 3.82%. In the last reported quarter, MRK beat earnings estimates by 3.26%. Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Merck has an Earnings ESP of -0.18% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for MRK's earnings is pegged at $2.01 per share. You can see the complete list of today's Zacks #1 Rank stocks here. Merck's top-line growth in the second quarter is likely to have been driven by higher sales of its blockbuster cancer drug Keytruda, attributable to additional indications and patient demand. Merck is scheduled to release its quarterly earnings results before the opening bell on July 29. Merck & Co., Inc. Price and Consensus Merck & Co., Inc. price-consensus-chart | Merck & Co., Inc. Quote AstraZeneca AstraZeneca has a mixed earnings track recordover the trailing four quarters. The company's earnings beat estimates in three of the last four quarters, missing the mark on one occasion. On average, AZN registered an earnings surprise of 4.24% in the last four quarters. In the last reported quarter, AstraZeneca beat earnings estimates by 12.73%. AstraZeneca has an Earnings ESP of -0.64% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for AZN's earnings is pegged at $1.09 per share. Sales of AstraZeneca's key medicines, mainly cancer drugs — Lynparza, Tagrisso and Imfinzi — and diabetes medicine Farxiga, are expected to have driven the company's top line in the second quarter, backed by strong demand trends. AstraZeneca is scheduled to release its quarterly earnings results before the opening bell on July 29. AstraZeneca PLC Price and Consensus AstraZeneca PLC price-consensus-chart | AstraZeneca PLC Quote Bristol Myers Bristol Myers has an excellent earnings track record. BMY's earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 20.16%. In the last reported quarter, Bristol Myers' earnings surpassed estimates by 19.21%. Bristol Myers has an Earnings ESP of -7.92% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for BMY's earnings is pegged at $1.18 per share. Bristol Myers' revenues in the second quarter of 2025 are likely to have been impacted by a decline in sales from its legacy drugs, which include Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane, among others. However, the expected decline is likely to have been partially offset by an increase in the sales of BMY's growth products like Opdivo, Yervoy, Reblozyl, Breyanzi, Zeposia, Opdualag and others. Bristol Myers is slated to release its quarterly earnings results before the opening bell on July 31. Bristol Myers Squibb Company Price and Consensus Bristol Myers Squibb Company price-consensus-chart | Bristol Myers Squibb Company Quote AbbVie AbbVie has an impeccable earnings track record to date. ABBV's earnings beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 2.55%. In the last reported quarter, AbbVie's earnings beat estimates by 2.93%. AbbVie has an Earnings ESP of 0.00% and a Zacks Rank #3 at present. The Zacks Consensus Estimate for ABBV's earnings is pegged at $2.89 per share. AbbVie's top line is expected to have been driven by robust sales of key drugs Rinvoq, Skyrizi, Venclexta and Vraylar, coupled with significant contributions from newer drugs, namely Ubrelvy, Elahere, Epkinly and Qulipta. ABBV is scheduled to report its quarterly earnings results on July 31, before the opening bell. AbbVie Inc. Price and Consensus AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote Moderna Moderna has an excellent earnings track record. It beat earnings estimates in each of the last four quarters, delivering an average earnings surprise of 31.60%. In the last reported quarter, MRNA beat earnings estimates by 13.70%. Moderna has an Earnings ESP of +7.22% and a Zacks Rank #3 at present, indicating a positive surprise this time around. The Zacks Consensus Estimate for MRNA's loss per share is pegged at $2.99. Moderna's second-quarter revenues are expected to have been driven by sales of its COVID-19 vaccine, Spikevax. However, with declining demand for COVID-related products, investors are advised to focus more on updates regarding the company's broader pipeline. Moderna is slated to release its quarterly earnings results before the opening bell on Aug. 1. Moderna, Inc. Price and Consensus Moderna, Inc. price-consensus-chart | Moderna, Inc. Quote Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Moderna, Inc. (MRNA) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
